Spruce Biosciences Inc. Common Stock (SPRB)

About SPRB

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder char…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

22

Website

sprucebio.com/

Fundamentals

1-day range

$59.9$62.98

Market cap

$127.76M

P/E (trailing)

—

P/E (forward)

7.44

EPS (trailing)

$-38.31

Dividend yield

—

Beta

3.40

Avg. volume

68.0K

Forecasts

8 analyst ratings

Spruce Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SPRB

  Spruce Biosciences Inc. Common Stock

  $60.05

  ▼ 5.13%
  Market cap $127.76MP/E —
  $7$240
• IFRX

  InflaRx N.V. Common Stock

  $2.22

  ▼ 2.20%
  Market cap $124.34MP/E —
  $0.7984$2.95
• EQ

  Equillium Inc. Common Stock

  $2.39

  ▼ 2.65%
  Market cap $134.04MP/E —
• GNLX

  Genelux Corporation Common Stock

  $2.66

  ▼ 7.64%
  Market cap $121.07MP/E —
  $2.29$8.54
• HURA

  TuHURA Biosciences Inc. Common Stock

  $2.11

  ▼ 1.17%
  Market cap $134.69MP/E —
  $0.41$3.43
• PMN

  ProMIS Neurosciences Inc. Common Shares (ON)

  $13.79

  ▼ 1.43%
  Market cap $119.54MP/E —
  $6.27$27.4
• VTVT

  vTv Therapeutics Inc. Class A Common Stock

  $32.17

  ▼ 1.92%
  Market cap $136.33MP/E 55.59
  $15.79$44

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type B
  benzinga · 8/26/2026
• Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104
  Benzinga · 8/17/2026
• Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144
  Benzinga · 8/13/2026
• SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q2 EPS $(6.68) Misses $(5.80) Estimate
  Benzinga · 8/12/2026

• Quartel Adrian W · July 27, 2026 · Grant

  13.0K
• Javier B. Szwarcberg · June 30, 2026 · Grant

  266 @ $4.53
• Walbert Keli · May 21, 2026 · Grant

  1.7K
• Barretto-Ko Percival · May 21, 2026 · Grant

  1.7K
• SIMPSON CAMILLA V · May 21, 2026 · Grant

  1.7K
• GREY MICHAEL G · May 21, 2026 · Grant

  1.7K
• Daniel K. Spiegelman · May 21, 2026 · Grant

  1.7K
• Hooks Corwin Dale · March 9, 2026 · Grant

  11.0K

Institutional Ownership

March 31, 2026

Total shares held

699.4K

Total value held

$45.71M

Institutional holders

30